Millennium uses Mersana's Fleximer ADC platform for cancer drug development; deal ends
Executive Summary
Mersana Therapeutics Inc. (antibody-drug conjugates) granted Takeda Pharmaceutical Co. Ltd. division Millennium: The Takeda Oncology Co. (also known as Millennium Pharmaceuticals) access to its Fleximer ADC technology for the development of new cancer therapies.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
-
Biotechnology
- Nanotechnology, Chips, etc.
-
Large Molecule
- Antibodies
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice